secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biohaven Ltd. (BHVN)
CIK:        0001935979
Form:       8-K
Filed at:   2025-08-22T23:59:59+00:00
Accession:  0001935979-25-000080
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA cancels advisory committee meeting for Biohaven's troriluzole NDA; decision still Q4 2025
--------------------------------------------------------------------------------

- FDA informed Biohaven on Aug 21, 2025 that an advisory committee meeting is no longer needed for troriluzole NDA review.
- Previously, FDA had extended PDUFA by 3 months (to Q4 2025) and planned an AdComm.
- Troriluzole is for treatment of adult Spinocerebellar Ataxia (SCA).
- FDA's expected decision remains during Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1935979/000193597925000080/0001935979-25-000080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1935979/000193597925000080/bhvn-20250821.htm
  HTML page:      https://secwatch.observer/filing/0001935979-25-000080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer